News

"This is the second jurisdiction in which we have elected to file for Orphan Designation," said Dr. Brad Thompson , President and CEO of Oncolytics. "The EMA serves

L-Bcl-2 is a liposomal encapsulated oligonucleotide targeted to the translation initiation site of human Bcl-2 mRNA. The antisense oligonucleotide in L-Bcl-2 is a nuclease-resistant, hydrophobic analog of phosphodiesters

EpiVax and Novozymes Biopharma today announced that they have entered a license agreement for the development of novel treatments for autoimmune diseases. The agreement follows two years of

IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc. IMBRUVICA (ibrutinib) is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton’s tyrosine

Under the deal, Tekmira’s Ebola drug will be made available in West Africa for clinical trials which are expected to start in early 2015. Funded by the Wellcome

The company said that around 78 patients will be enrolled in the randomized, double-blind, placebo controlled Phase II trial that will be conducted in the US, Europe and

The strategic alliance includes the granting of manufacturing rights by ProMetic to GENERIUM for several plasma-derived biopharmaceuticals using ProMetic’s proprietary PPPS technology. In addition, ProMetic will provide training

The drug will be indicated for ITP patients who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. ITP is characterized by a low platelet count and

"RAPIVAB is the first neuraminidase inhibitor that has shown to be safe and effective as a single-dose, i.v. therapy for patients with acute, uncomplicated influenza, and represents the